Monday, April 13, 2020 1:24:48 PM
Contrary to what some here have posted, there is no dilution on-going to the float. While the shares from the offering WILL increase the O/S, the float (the shares we buy and sell) is NOT getting diluted...
From the 10-K under NOTE 11 - SUBSEQUENT EVENTS
On April 1, 2020, the Company sold 3,000,000 shares of common stock for total cash proceeds of $15,000. The shares were sold pursuant to the offering statement recently filed with the SEC.
If you look at volume from April 1, 2020 the volume was 619,270
https://www.nasdaq.com/market-activity/stocks/rmsl/historical
Additionally, while it is true these shares are not "restricted" per the offering filing, they are NOT being sold on the open market into the float. Therefore they must be Private Placement shares which are sold to "qualified investors" at .005. See offering filing for who can be a "qualified investor." (1 mil+ net worth excluding home value, etc...)
And while true, after these shares are sold to "qualified investors" they can be sold, selling is NOT going on. And quite frankly, why would someone who qualifies to buy these shares directly from the company at .005 turn around and sell these shares at .006 for a measly 20%? These most likely are long-term investors who see the massive potential in this company and probably colleagues/associates/friends of CEO Tom Wood and management.
All IMO but I think im spot on here... Thoughts anyone?
$RMSL
Recent RMSL News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/14/2024 01:10:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/14/2024 05:15:18 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 09:58:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:38:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:26:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 07:02:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:10:55 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:12:01 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 07/14/2023 01:58:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2023 07:21:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM